ストックスクリーナーアプリを入手
2.00
4.76%
-0.10
前日終値:
$2.10
開ける：
$2.1
24時間の取引高:
7.76M
Relative Volume:
0.68
時価総額：
$690.31M
収益：
$22,000
当期純損益:
$-173.76M
株価収益率:
-2.6038
EPS:
-0.7681
ネットキャッシュフロー:
$-109.53M
1週間 パフォーマンス:
-3.85%
1か月 パフォーマンス:
+12.36%
6か月 パフォーマンス:
+16.96%
1年 パフォーマンス:
+58.73%
1日の値動き範囲:
$1.94
$2.10
1週間の範囲:
$1.94
$2.185
52週間の値動き範囲:
$0.9842
$4.46
Allogene Therapeutics Inc Stock (ALLO) Company Profile
名前
Allogene Therapeutics Inc
セクター
電話
(650) 457-2700
住所
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.00 | 690.31M | 22,000 | -173.76M | -109.53M | -0.7681 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2026-04-10 | 再開されました | Jefferies | Buy |
| 2026-01-09 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-05-14 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | 再開されました | Oppenheimer | Outperform |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-01-05 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-01-05 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 開始されました | Citigroup | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-01-06 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | ダウングレード | BofA Securities | Buy → Underperform |
| 2022-08-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | アップグレード | Goldman | Neutral → Buy |
| 2022-06-03 | 開始されました | Robert W. Baird | Neutral |
| 2022-02-28 | 繰り返されました | B. Riley Securities | Buy |
| 2021-10-20 | 開始されました | Cowen | Outperform |
| 2021-10-08 | ダウングレード | Goldman | Buy → Neutral |
| 2021-10-08 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-23 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 再開されました | Jefferies | Buy |
| 2021-05-20 | アップグレード | Truist | Hold → Buy |
| 2021-05-14 | 開始されました | B. Riley Securities | Buy |
| 2021-01-26 | アップグレード | Stifel | Hold → Buy |
| 2020-12-10 | 再開されました | H.C. Wainwright | Buy |
| 2020-11-24 | 開始されました | BofA Securities | Buy |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-06-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-19 | アップグレード | ROTH Capital | Neutral → Buy |
| 2020-05-15 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-05-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-14 | ダウングレード | SunTrust | Buy → Hold |
| 2020-04-13 | 開始されました | SunTrust | Buy |
| 2020-03-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-05 | 開始されました | Stifel | Hold |
| 2020-02-24 | 開始されました | Berenberg | Hold |
| 2019-12-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-11-04 | 開始されました | Canaccord Genuity | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-05 | 開始されました | ROTH Capital | Neutral |
| 2019-05-31 | 開始されました | Guggenheim | Neutral |
| 2019-05-23 | 開始されました | Stifel | Hold |
| 2019-03-29 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Allogene Therapeutics Inc (ALLO) 最新ニュース
Allogene Therapeutics (ALLO) price target increased by 16.66% to 8.83 - MSN
Cancer cell therapy pioneer Allogene’s new CEO is talking about a new revolution - The Business Journals
Form 4 Allogene Therapeutics Inc For: 6 July By Investing.com - Investing.com Canada
Allogene Therapeutics (ALLO) CEO granted 476,190 options and 134,530 RSUs - Stock Titan
ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ - Stocktwits
Allogene Therapeutics shows promise with ALPHA3 trial and ALLO-329, cutting losses and extending cash runway. - Pluang
Allogene Therapeutics: High-Upside Bet On The Next Wave Of CAR-T Innovation (NASDAQ:ALLO) - Seeking Alpha
ALLO News | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill
Allogene at H.C. Wainwright conference: cema-cel data lift strategy By Investing.com - Investing.com Nigeria
Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView
Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions - Yahoo Finance
Price to earnings forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView
Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Enterprise value to revenue forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Price to book forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView
Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Allogene Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLO) - TradingView
Why is Allogene Therapeutics (ALLO) down 12.2% since last earnings report? - MSN
ALLO Forecast — Price Target — Prediction for 2027 - TradingView
Allogene Therapeutics unveils strategy to overcome autologous CAR T cell therapy limitations - Traders Union
Allogene Therapeutics (ALLO) Edges Higher Near Key Resistance LevelInsider Selling Alerts - dars.gov.et
Recent pharma exec shake-ups signal strategic shifts - Pharma Voice
Form 4 Allogene Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria
Allogene (ALLO) director Kazam converts 47,700 RSUs and receives 95,400-unit equity grant - Stock Titan
Allogene Therapeutics (NASDAQ: ALLO) grants director 95,400 RSUs - Stock Titan
Allogene Therapeutics (ALLO) director receives 144,400 stock options grant - Stock Titan
Allogene Therapeutics (ALLO) director receives 95,400 RSU equity award - Stock Titan
Allogene (ALLO) director Owen Witte awarded 95,400 RSUs with deferred delivery - Stock Titan
[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan
Allogene (ALLO) director awarded 95,400 RSUs with deferred share delivery - Stock Titan
Form 424B5 Allogene Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Allogene Therapeutics (NASDAQ: ALLO) doubles authorized shares and files $135M ATM plan - Stock Titan
Allogene (NASDAQ: ALLO) launches $135M ATM program with TD Cowen at $2.00 ref - Stock Titan
Allogene Therapeutics Activates First Clinical Sites for Pivotal Phase 2 Trial of Cema-Cel - CRISPR Medicine News
ALLO: All proposals, including director elections and share increase, were approved without contest - TradingView
ALLO: All proposals passed, including director elections and share authorization increase - TradingView
Allogene Therapeutics Inc (ALLO) Institutional Confidence - TradingKey
Allogene Therapeutics Inc (ALLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allogene Therapeutics Inc (ALLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Allogene Therapeutics Inc (ALLO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease - Insider Monkey
Allogene Therapeutics Inc (ALLO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Allogene Therapeutics Inc (ALLO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Allogene Therapeutics Inc (ALLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Allogene Therapeutics Stock Surges on Optimistic Trial Results and Price Target Increase - timothysykes.com
Allogene Therapeutics Inc (ALLO) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):